These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 26660432)

  • 1. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.
    Wouters BJ; Delwel R
    Blood; 2016 Jan; 127(1):42-52. PubMed ID: 26660432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia.
    Li Y; Xu Q; Lv N; Wang L; Zhao H; Wang X; Guo J; Chen C; Li Y; Yu L
    J Hematol Oncol; 2017 Feb; 10(1):41. PubMed ID: 28153026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors.
    Xu QY; Yu L
    Chin Med J (Engl); 2020 Mar; 133(6):699-715. PubMed ID: 32044818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision therapy for acute myeloid leukemia.
    Yang X; Wang J
    J Hematol Oncol; 2018 Jan; 11(1):3. PubMed ID: 29301553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia.
    Newcombe AA; Gibson BES; Keeshan K
    Exp Hematol; 2018 Jul; 63():1-11. PubMed ID: 29608923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic mechanisms in AML - a target for therapy.
    Oki Y; Issa JP
    Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications.
    Yang X; Wong MPM; Ng RK
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31527484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic alterations in acute myeloid leukemias.
    Mehdipour P; Santoro F; Minucci S
    FEBS J; 2015 May; 282(9):1786-800. PubMed ID: 25369368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the understanding and treatment of acute myeloid leukemia.
    Watts J; Nimer S
    F1000Res; 2018; 7():. PubMed ID: 30135719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development.
    Tsai CT; So CW
    Oncogene; 2017 Mar; 36(13):1753-1759. PubMed ID: 27593928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic Abnormalities in Acute Myeloid Leukemia and Leukemia Stem Cells.
    Xu J; Hang X; Wu B; Chen C; Liu Y
    Adv Exp Med Biol; 2019; 1143():173-189. PubMed ID: 31338820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic therapies in acute myeloid leukemia: where to from here?
    Fennell KA; Bell CC; Dawson MA
    Blood; 2019 Nov; 134(22):1891-1901. PubMed ID: 31697822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
    Hou HA; Tien HF
    Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Aberrant DNA methylation and its targeted therapy in acute myeloid leukemia].
    Li X; Zhu L; Ye X
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(4):387-394. PubMed ID: 27868412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updates on DNA methylation modifiers in acute myeloid leukemia.
    Contieri B; Duarte BKL; Lazarini M
    Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research progress of epigenetic drug decitabine in AML].
    Zhang R; Li HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1467-71. PubMed ID: 25338609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets.
    Reikvam H; Hoang TT; Bruserud Ø
    Expert Rev Hematol; 2015 Jun; 8(3):315-27. PubMed ID: 25901742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecularly targeted therapy in acute myeloid leukemia.
    Gill H; Leung AY; Kwong YL
    Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.